Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 4, 1998, Pages 481-484

  Schmitz, Franz Josef ^a,b   Hofmann, Basia ^a   Hansen, Birgit ^a   Scheuring, Sibylle ^a   Lückefahr, Marc ^a   Klootwijk, Mirjam ^b   Verhoef, Jan ^b   Fluit, Ad ^b   Heinz, Hans Peter ^a   Köhrer, Karl ^a   Jones, Mark E ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; DRUG EFFICACY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA, BACTERIAL; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS;

EID: 15444352824     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.4.481     Document Type: Article

References (10)

1. Goldstein, F. W. & Acar, J. F. (1995). Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49, Suppl. 2, 36-42.
2. Kaatz, G. W. & Seo, S. M. (1995). Inducible norA-mediated multidrug resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 2650-5.
3. Ito, H., Yoshida, H., Bogaki-Shonnai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 38, 2014-23.
4. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
5. Blanche, F., Cameron, B., Bernard, F. X., Maton, L., Manse, B., Ferrero, L. et al. (1996). Differential behaviours of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrobial Agents and Chemotherapy 40, 2714-20.
6. Schmitz, F. J., Hofmann, B., Verhoef, J., Finken-Eigen, M., Idel, H., Hadding, U. et al. (1997). Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR. Journal of Medical Microbiology 46, 773-8.
7. Schmitz, F. J., Steiert, M., Tichy, H.-V., Verhoef, J., Heinz, H.-P., Köhrer, K. et al. (1998). Comparison of six different genotypic methods for the typing of methicillin-resistant Staphylococcus aureus isolates from 11 hospitals in the Düsseldorf area. Journal of Medical Microbiology, in press.
8. National Committee for Clinical Laboratory Standards. (1991). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Second Edition: Approved Standard M7-A2. NCCLS, Villanova, PA.
9. Yamagishi, J., Kojima, T., Oyamada, Y., Fujimoto, K., Hattori, H., Nakumara, S. et al. (1996). Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 40, 1157-63.
10. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.